<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643303</url>
  </required_header>
  <id_info>
    <org_study_id>LUD2014-011</org_study_id>
    <nct_id>NCT02643303</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers</brief_title>
  <official_title>A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research Institute, New York City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and
      the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment
      (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable,
      biopsy-accessible cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2016</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) at 24 weeks</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Analyzed by irRECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>up to 15 months</time_frame>
    <description>Adverse events according to CTCAE V4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy by objective response rate (ORR)</measure>
    <time_frame>up to 15 months</time_frame>
    <description>assessed by irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy by progression-free survival (PFS)</measure>
    <time_frame>up to 15 months</time_frame>
    <description>assessed by irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy by overall survival (OS)</measure>
    <time_frame>up to 15 months</time_frame>
    <description>assessed by irRECIST</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Cutaneous T-Cell Lymphoma</condition>
  <condition>Melanoma</condition>
  <condition>Renal Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Testicular Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1, Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Durvalumab + IT/IM polyICLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Durvalumab + IV Tremelimumab + IT/IM polyICLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Durvalumab + IT Tremelimumab + IT/IM polyICLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the recommended combination doses of the triplet dosing regimen has been determined in Cohort 1C, subsequent subjects will be enrolled into Cohort 2 to receive the recommended combination doses of both checkpoint antibodies in combination with polyICLC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <arm_group_label>Phase 1, Cohort 1A</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly ICLC</intervention_name>
    <arm_group_label>Phase 1, Cohort 1A</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
    <other_name>Hiltonol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have histologic confirmation of advanced, biopsy-accessible, measurable
             cancers of the following histologies:

               -  Non-viral-associated head and neck squamous cell carcinoma (HNSCC) or
                  HPV-associated HNSCC after failure of prior therapy

               -  Locally recurrent or metastatic breast cancer

               -  Sarcoma

               -  Merkel Cell Carcinoma (MCC)

               -  Cutaneous T cell Lymphoma (CTCL)

               -  Melanoma after failure of available therapies

               -  GU cancers with accessible metastases (e.g., bladder, renal)

               -  Any solid tumors with masses that are accessible

          2. Subjects with measurable disease, must have at least 2 lesions (1 measurable lesion
             and 1 biopsy/injectable lesion, which will not need to be measurable).

          3. Any number of prior systemic therapies.

          4. ECOG performance status 0-1.

          5. Laboratory parameters for vital functions should be in the normal range or not
             clinically significant.

        Exclusion Criteria:

          1. Prior treatment with combination CTLA-4 and PD-1/PD-L1 blockade, with the exception of
             subjects with melanoma.

          2. Participants may not have been treated intratumorally with polyICLC.

          3. Subjects with history or evidence upon physical examination of central nervous system
             (CNS) disease, including primary brain tumor, seizures not controlled with standard
             medical therapy, any active brain metastases, or, within 6 months of the first date of
             treatment on this study, history of cerebrovascular accident (CVA, stroke), transient
             ischemic attack (TIA) or subarachnoid hemorrhage.

          4. Active, suspected or prior documented autoimmune disease, clinically significant
             cardiovascular disease or clinically uncontrolled hypertension.

          5. History of pneumonitis or interstitial lung disease or any unresolved immune-related
             adverse events following prior biological therapy.

          6. Other malignancy within 2 years prior to entry into the study, except for those
             treated with surgical therapy only (e.g., localized low-grade cervical or prostate
             cancers).

          7. Subjects with clinical symptoms or signs of gastrointestinal obstruction and/or who
             require drainage gastrostomy tube and/or parenteral hydration or nutrition.

          8. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
             Hepatitis B or C without evidence of active infection may be allowed.

          9. History of severe allergic reactions to any unknown allergens or any components of the
             study drugs.

         10. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
             disorders).

         11. History of allogeneic organ transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L Slingluff, Jr., MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nina Bhardwaj, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tisch Cancer Institute Ichan School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Aufiero Ramirez</last_name>
    <phone>212-450-1515</phone>
    <email>clintrialinformation@licr.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Robinson</last_name>
      <email>robinss@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Mahmutovic</last_name>
      <email>am6bd@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Durvalumab</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>Tremelimumab</keyword>
  <keyword>PolyICLC</keyword>
  <keyword>Hiltonol</keyword>
  <keyword>Locally Recurrent Breast Cancer</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>In Situ</keyword>
  <keyword>CTLA-4 Antibody</keyword>
  <keyword>PD-L1 Antibody</keyword>
  <keyword>TLR3 Agonist</keyword>
  <keyword>CTCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

